Perceptive Advisors LLC increased its holdings in Blueprint Medicines Corp (NASDAQ:BPMC) by 168.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,140,434 shares of the biotechnology company’s stock after acquiring an additional 715,773 shares during the quarter. Blueprint Medicines makes up 2.9% of Perceptive Advisors LLC’s portfolio, making the stock its 7th biggest position. Perceptive Advisors LLC owned 2.66% of Blueprint Medicines worth $86,000,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Blueprint Medicines by 57.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $173,000. First Mercantile Trust Co. acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $183,000. Tower Research Capital LLC TRC lifted its stake in shares of Blueprint Medicines by 942.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Turner Investments LLC acquired a new position in shares of Blueprint Medicines in the third quarter worth about $209,000. Institutional investors and hedge funds own 97.79% of the company’s stock.
Shares of Blueprint Medicines Corp (BPMC) opened at $101.05 on Monday. Blueprint Medicines Corp has a one year low of $34.38 and a one year high of $101.38. The company has a quick ratio of 15.98, a current ratio of 15.98 and a debt-to-equity ratio of 0.02.
BPMC has been the topic of several recent analyst reports. Zacks Investment Research upgraded Blueprint Medicines from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research note on Monday, January 8th. Goldman Sachs Group boosted their price target on Blueprint Medicines from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. Raymond James Financial set a $82.00 price target on Blueprint Medicines and gave the stock a “buy” rating in a research note on Sunday, December 10th. BidaskClub upgraded Blueprint Medicines from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Finally, Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, February 21st. Two research analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Blueprint Medicines currently has a consensus rating of “Buy” and an average price target of $84.20.
In other news, Director Daniel Lynch sold 17,500 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the sale, the director now directly owns 202,812 shares in the company, valued at approximately $15,178,450.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kate Haviland sold 6,775 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $74.93, for a total value of $507,650.75. Following the sale, the insider now owns 12,649 shares in the company, valued at $947,789.57. The disclosure for this sale can be found here. Insiders have sold 81,775 shares of company stock worth $6,871,251 in the last 90 days. 3.40% of the stock is currently owned by insiders.
Blueprint Medicines Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.